GAITHERSBURG, Md., March 2, 2017 /PRNewswire/ -- MaxCyte, a US-based global company dedicated to accelerating the discovery,
Using MaxCyte's unique, rapid-manufacture CARMA platform in immuno-oncology, MaxCyte and its collaborators at the Johns Hopkins Kimmel Cancer Center demonstrated that preclinical in vivo testing of CARMA-hMeso (i.e., mesothelin-specific mRNA CAR-transfected peripheral blood lymphocytes) containing mesothelin-expressing tumor cells resulted in killing of tumor cells and in increased overall survival; with multiple repeat weekly administration of CARMA-hMeso permitting prolonged control over tumor growth and increased overall survival compared to a single administration.
"These data represent a major pre-clinical milestone for MaxCyte's CARMA program as the results demonstrate the ability of a CARMA immunotherapy to effectively inhibit tumor growth and prolong survival in an animal model of disease," said Doug Doerfler, President & Chief Executive Officer. "The data provide a strong scientific foundation for translational development of our rapid-manufacture CARMA platform to quickly develop tumor-targeted immunotherapies using peripheral blood lymphocytes. We can control 'on-target, off-tumor' toxicities, while reducing manufacturing cost and complexity for therapies targeting both solid cancers and hematological malignancies, beyond B-cell tumors."
Data will be shared via a poster (Permanent Abstract Number: 3748) at the AACR Annual Meeting 2017 as follows:
Session: "Innate Effectors in Immunity to Cancer"
Date: Tuesday, April 4, 2017
Time: 8:00 a.m. - 12:00 p.m. ET
About MaxCyte MaxCyte is a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines.
For more information, visit http://www.maxcyte.com/
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/maxcyte-to-present-pre-clinical-carma-data-at-aacr-meeting-300416595.html
Subscribe to our Free Newsletters!
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...View All